Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non small cell lung cancer (NSCLC) in certain situations, as a first line treatment for metastatic bladder cancer in patients who cannot receive cisplatin based chemotherapy and have high levels of PD L1, as a second line treatment for head and neck squamous cell carcinoma (HNSCC), after platinum based chemotherapy, for the treatment of adult and pediatric patients with refractory classic Hodgkins lymphoma (cHL), and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.
